MA5-14973

antibody from Invitrogen Antibodies

Targeting: STAT5A MGF, STAT5

Western blot (Supportive data in Antibodypedia)

Immunoprecipitation (Recommended by provider)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-14973

Provider

Invitrogen Antibodies

Product name

Phospho-STAT5 alpha (Tyr694) Monoclonal Antibody (S.161.3)

Antibody type

Monoclonal

Antigen

Synthetic peptide

Description

It is not recommended to aliquot this antibody.

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Antibody clone number

S.161.3

Vial size

100 µL

Concentration

380 µg/mL

Storage

-20°C

References

Submitted references

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3.

Wachholz V, Mustafa AM, Zeyn Y, Henninger SJ, Beyer M, Dzulko M, Piée-Staffa A, Brachetti C, Haehnel PS, Sellmer A, Mahboobi S, Kindler T, Brenner W, Nikolova T, Krämer OH
Archives of toxicology 2022 Jan;96(1):177-193

---

Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition.

Pons M, Zeyn Y, Zahn S, Mahendrarajah N, Page BDG, Gunning PT, Moriggl R, Brenner W, Butter F, Krämer OH
Cancers 2021 Jul 10;13(14)

---

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B
Science (New York, N.Y.) 2017 Dec 1;358(6367)

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis was performed on whole cell extracts (30 µg lysate) of K-562 (Lane 1), K-562 treated with Imatinib (1 uM for 2 h) (Lane 2), Imatinib (5 uM for 2 h) (Lane 3), Dasatinib (1 mM for 4 h) (Lane 4), and Tofacitinib (1 umol/M for 48 h) (Lane 5), HEL 92.1.7 (Lane 6) and HEL 92.1.7 treated with Tofacitinib (1 umol/M for 48 h) (Lane 7). The blot was probed with Anti-Phospho-STAT5 alpha (Tyr694) Monoclonal Antibody (Product # MA5-14973, 1:500 dilution) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.25 µg/ml, 1:4000 dilution). A 90 kDa band corresponding to Phospho-STAT5 alpha (Tyr694) was observed in K-562 and HEL 92.1.7 at basal levels. Expression was reduced upon treatment with tyrosine kinase inhibitors Imatinib and Dasatinib in K-562. Whereas, treatment with JAK-inhibitor Tofacitinib reduced expression in HEL 92.17 but not K-562, which is resistant to the drug.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of Phospho-STAT5 pTyr694 in extracts from K562 cells, untreated or treated with an Imatinib-inhibitor, using Phospho-STAT5 pTyr694 monoclonal antibody (Product # MA5-14973) (top) and a Stat5 monoclonal antibody (bottom).

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical analysis of Phospho-STAT5 pTyr694 in paraffin-embedded human breast carcinoma using a Phospho-STAT5 pTyr694 monoclonal antibody (Product # MA5-14973).

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometric analysis of Phospho-STAT5 pTyr694 in untreated (green) or Imatinib ST1571-treated (blue) K562 cells using a Phospho-STAT5 pTyr694 monoclonal antibody (Product # MA5-14973).